Archives of Clinical Infectious Diseases

Published by: Kowsar

Evaluation of the Ability of Malassezia Species in Biofilm Formation

Mahdi Zareei 1 , Shahla Roudbar Mohammadi 1 , * , Shirin Shahbazi 2 , Maryam Roudbary 3 and Zeinab Borjian Borujeni 4
Authors Information
1 Department of Medical Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 Department of Medical Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: August 2018, 13 (4); e62223
  • Published Online: July 31, 2017
  • Article Type: Research Article
  • Received: July 31, 2016
  • Revised: March 11, 2017
  • Accepted: March 14, 2017
  • DOI: 10.5812/archcid.62223

To Cite: Zareei M, Roudbar Mohammadi S, Shahbazi S, Roudbary M, Borjian Borujeni Z. Evaluation of the Ability of Malassezia Species in Biofilm Formation, Arch Clin Infect Dis. 2018 ; 13(4):e62223. doi: 10.5812/archcid.62223.

Copyright © 2017, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Figueredo LA, Cafarchia C, Otranto D. Antifungal susceptibility of Malassezia pachydermatis biofilm. Med Mycol. 2013;51(8):863-7. doi: 10.3109/13693786.2013.805440. [PubMed: 23834283].
  • 2. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol. 2006;9(6):588-94. doi: 10.1016/j.mib.2006.10.003. [PubMed: 17055772].
  • 3. Chandra J, Zhou G, Ghannoum MA. Fungal biofilms and antimycotics. Curr Drug Targets. 2005;6(8):887-94. doi: 10.2174/138945005774912762. [PubMed: 16375672].
  • 4. Figueredo LA, Cafarchia C, Desantis S, Otranto D. Biofilm formation of Malassezia pachydermatis from dogs. Vet Microbiol. 2012;160(1-2):126-31. doi: 10.1016/j.vetmic.2012.05.012. [PubMed: 22682201].
  • 5. Cannizzo FT, Eraso E, Ezkurra PA, Villar-Vidal M, Bollo E, Castella G, et al. Biofilm development by clinical isolates of Malassezia pachydermatis. Med Mycol. 2007;45(4):357-61. doi: 10.1080/13693780701225767. [PubMed: 17510859].
  • 6. Larocco M, Dorenbaum A, Robinson A, Pickering LK. Recovery of Malassezia pachydermatis from eight infants in a neonatal intensive care nursery: clinical and laboratory features. Pediatr Infect Dis J. 1988;7(6):398-401. doi: 10.1097/00006454-198806000-00006. [PubMed: 3134645].
  • 7. Mickelsen PA, Viano-Paulson MC, Stevens DA, Diaz PS. Clinical and microbiological features of infection with Malassezia pachydermatis in high-risk infants. J Infect Dis. 1988;157(6):1163-8. doi: 10.1093/infdis/157.6.1163. [PubMed: 3373021].
  • 8. Welbel SF, McNeil MM, Pramanik A, Silberman R, Oberle AD, Midgley G, et al. Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit. Pediatr Infect Dis J. 1994;13(2):104-8. doi: 10.1097/00006454-199402000-00005. [PubMed: 8190533].
  • 9. Chryssanthou E, Broberger U, Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr. 2001;90(3):323-7. doi: 10.1080/080352501300067712. [PubMed: 11332175].
  • 10. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167-93. doi: 10.1128/CMR.15.2.167-193.2002. [PubMed: 11932229].
  • 11. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol. 2002;19(3):139-43. [PubMed: 12825991].
  • 12. Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol. 2005;15(12):R453-5. doi: 10.1016/j.cub.2005.06.020. [PubMed: 15964263].
  • 13. Curvale-Fauchet N, Botterel F, Legrand P, Guillot J, Bretagne S. Frequency of intravascular catheter colonization by Malassezia spp. in adult patients. Mycoses. 2004;47(11-12):491-4. doi: 10.1111/j.1439-0507.2004.01047.x. [PubMed: 15601455].
  • 14. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res. 2001;80(3):903-8. doi: 10.1177/00220345010800031101. [PubMed: 11379893].
  • 15. Rajendran R, May A, Sherry L, Kean R, Williams C, Jones BL, et al. Integrating Candida albicans metabolism with biofilm heterogeneity by transcriptome mapping. Sci Rep. 2016;6:35436. doi: 10.1038/srep35436. [PubMed: 27765942].
  • 16. Zarei Mahmoudabadi A, Zarrin M, Kiasat N. Biofilm Formation and Susceptibility to Amphotericin B and Fluconazole in Candida albicans. Jundishapur J Microbiol. 2014;7(7). e17105. doi: 10.5812/jjm.17105. [PubMed: 25368806].
  • 17. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun. 2002;70(2):878-88. doi: 10.1128/IAI.70.2.878-888.2002. [PubMed: 11796623].
  • 18. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001;183(18):5385-94. [PubMed: 11514524].
  • 19. Released I. IBM SPSS Statistics for Windows. 20. Armonk, NY: IBM Corp; 2013.
  • 20. Weiss SJ, Schoch PE, Cunha BA. Malassezia furfur fungemia associated with central venous catheter lipid emulsion infusion. Heart Lung. 1991;20(1):87-90. [PubMed: 1988397].
  • 21. Shparago NI, Bruno PP, Bennett J. Systemic Malassezia furfur infection in an adult receiving total parenteral nutrition. J Am Osteopath Assoc. 1995;95(6):375-7. [PubMed: 7615409].
  • 22. Iatta R, Cafarchia C, Cuna T, Montagna O, Laforgia N, Gentile O, et al. Bloodstream infections by Malassezia and Candida species in critical care patients. Med Mycol. 2014;52(3):264-9. doi: 10.1093/mmy/myt004. [PubMed: 24576998].
  • 23. Plumb JA. Cell sensitivity assays: the MTT assay. Cancer Cell Culture: Methods and Protocols. 2004. p. 165-9.
  • 24. Fischer J, Prosenc MH, Wolff M, Hort N, Willumeit R, Feyerabend F. Interference of magnesium corrosion with tetrazolium-based cytotoxicity assays. Acta Biomater. 2010;6(5):1813-23. doi: 10.1016/j.actbio.2009.10.020. [PubMed: 19837191].
  • 25. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001;18(4):163-70. [PubMed: 15496122].
  • 26. Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods. 2010;83(2):89-105. doi: 10.1016/j.mimet.2010.08.018. [PubMed: 20816706].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments